NCT02269852

The Immunogenicity and Safety of 2013-2014 Seasonal Trivalent Influenza Vaccine

A Single-centered, Open-labeled, Phase 4 Study of a Northern Hemisphere 2013-2014 Seasonal Trivalent Influenza Inactivated Vaccine, Anflu®

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 182 (actual)
• Sponsor: Sinovac Biotech Co., Ltd · Industry
• Sex: All
• Age: 6 Months
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the immunogenicity and safety of Northern hemisphere 2013-2014 seasonal trivalent inactivated influenza vaccine in 60 healthy infants aged 6-35 months old, 60 healthy adults aged 18-60 years old, and 60 healthy seniors aged \> 60 years.

Conditions

• Influenza

Interventions

Type	Name	Description
BIOLOGICAL	trivalent seasonal influenza vaccine	* Infants: 0.25 ml/ dose; * Adults: 0.5 ml/ dose; * Seniors: 0.5 ml/ dose;

Timeline

• Start date: 2013-12-01
• Primary completion: 2014-04-01
• Completion: 2014-06-01
• First posted: 2014-10-21
• Last updated: 2015-09-21

Locations

1 site across 1 country: China